Improved Lipid Profiles and Maintenance of Virologic Control in Heavily Pretreated HIV‐Infected Patients Who Switched from Stavudine to Tenofovir Treatment
1Praxis St. Georg, Hamburg, and 2Institut für Medizinische Statistik, Informatik und Epidemiologie, Universität zu Köln, Germany; and 3HIV/AIDS Outpatient Clinic, Infectious Diseases, IRCCS Policlinico San Matteo Hospital, University of Pavia, Pavia, Italy
A retrospective chart analysis of 66 human immunodeficiency virus type 1 (HIV‐1)–infected patients whose treatment was switched from stavudine to tenofovir without any other treatment changes was conducted. The mean total cholesterol values decreased significantly within 3 months after the tenofovir substitution and remained significantly less than baseline values during 18 months of follow‐up (mean decrease, 36 mg/dL;
). Regimens containing tenofovir provided effective control of HIV‐1 infection, with stable CD4+ cell counts and continued suppression of plasma HIV‐1 level following the treatment switch from stavudine.
Received 12 June 2005; accepted 30 August 2005; electronically published 29 November 2005.
Cited by
Online publication date: 1-Feb-2008.
CrossRef
Online publication date: 1-Feb-2008.
CrossRef
Online publication date: 1-Oct-2007.
CrossRef
Online publication date: 1-Feb-2007.
CrossRef
Online publication date: 1-Feb-2007.
CrossRef
Online publication date: 1-Dec-2006.
CrossRef
Online publication date: 1-Oct-2006.
CrossRef
Online publication date: 1-Oct-2006.
CrossRef
Online publication date: 1-May-2006.
Online publication date: 1-May-2006.



